xmlns:atom="http://www.w3.org/2005/Atom" xmlns:atom="http://www.w3.org/2005/Atom"
169. In regulation 213 (amendment of regulation 281 (duties of authorisation holders and registration holders)) for paragraphs (b) and (c) substitute—U.K.
“(b)omit “or” at the end of sub-paragraph (c); and
(c)in sub-paragraph (d), after “for a medicinal product” insert—
“; or
(e)an EU marketing authorisation for a medicinal product.”.”.
Commencement Information
I1Sch. 2 para. 169 in force at 31.12.2020 immediately before IP completion day, see reg. 1